

## Disclosures

### Personal Commercial (9)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
abiomed	Consultant Fees/Honoraria	None (\$0)	<i>Invasive CV Angio and Interventions</i>
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ <i>Galileo</i>	None (\$0)	<i>General Cardiology</i>
Boston Scientific	Consultant Fees/Honoraria	None (\$0)	<i>Invasive CV Angio and Interventions</i>
Daiichi Sankyo	Research/Research Grants	None (\$0)	<i>General Cardiology</i>
Medtronic	Consultant Fees/Honoraria	None (\$0)	<i>Invasive CV Angio and Interventions</i>
<i>Spouse/Domestic Partner</i>			
Astra-Zeneca	Research/Research Grants ‡ <i>TWILIGHT</i>	None (\$0)	<i>General Cardiology</i>
Cardiovascular Systems Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Invasive CV Angio and Interventions</i>
Claret	Other - <i>Stock Options (&lt;1%)</i>	None (\$0)	<i>Invasive CV Angio and Interventions</i>
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>

### Personal Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
CardioVascular Research Foundation	Other - <i>Physician faculty</i>	None (\$0)	<i>Invasive CV Angio and Interventions</i>
SCAI	Other - <i>physician faculty</i>	None (\$0)	<i>Invasive CV Angio and Interventions</i>

### Clinical Trial Enroller (9)

Trial Name	Trial Sponsor	Trial Funding Source
Graftmaster	Abbott	
COAPT trial	Abbott	
Bioflow	Biotronik	
Parachute	CardioKinetix	
Corevalve SURTAVI	MEDTRONIC	
Spyral	MEDTRONIC	
Intrepid	MEDTRONIC	
AVERT trial	Osprey	
Renalguard	Renalguard	

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2016	Cause of death determination: arrhythmia vs reinfarction	Plaintiff † <i>Riggs, Elsworth &amp; Parker</i>	Mortality inquiry in a patient who left a hospital without being discharged and ended up expiring soon afterwards.	Significant (>= \$5,000)
2016	Stent thrombosis	Defendant † <i>Saxton &amp; Stump</i>	Cause of death consultation: stent thrombosis versus bowel necrosis	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

Certified Education Attestation | Signed on 11/27/2016

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/27/2016

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 11/27/2016

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 11/28/2016

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.